Literature DB >> 15507672

Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.

Marcia L Taylor1, Devinder Sehgal, Mark Raffeld, Harold Obiakor, Cem Akin, Rose G Mage, Dean D Metcalfe.   

Abstract

Mastocytosis is characterized by focal heterotypic clusters of mast cells and lymphocytes in the bone marrow and by a somatically acquired activating Kit mutation, D816V. The relationship of the occurrence of this mutation to the heterotypic clusters of mast cells and lymphocytes in bone marrow is unknown. We hypothesized that these two unique features of mastocytosis were related. To explore this hypothesis, laser capture microdissected mast cells, B cells, and T cells, from both lesional and non-lesional areas of bone marrow biopsy tissues from patients with mastocytosis, were examined for the D816V mutation in their DNA, using HinfI restriction digestion of nested PCR products amplified from extracts of dissected cells. The D816V mutation was detected in mast cells, B cells, and T cells from lesional but not non-lesional areas of bone marrow tissues. B cells obtained from lesional areas of tissue were also assessed for clonality and were found to at least represent an oligoclonal population. Thus, mast cells and lymphocytes within focal aggregates in the bone marrow of those with mastocytosis are more frequently positive for the codon 816 activating mutation. Further, the B cell population is oligoclonal, suggesting that clonal proliferation is unlikely to be the basis of clustering.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507672      PMCID: PMC1867480          DOI: 10.1016/S1525-1578(10)60529-6

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  23 in total

1.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.

Authors:  C Akin; A S Kirshenbaum; T Semere; A S Worobec; L M Scott; D D Metcalfe
Journal:  Exp Hematol       Date:  2000-02       Impact factor: 3.084

Review 2.  Lymphoid tissues and the immune system in mastocytosis.

Authors:  Y A Mekori
Journal:  Hematol Oncol Clin North Am       Date:  2000-06       Impact factor: 3.722

3.  Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene.

Authors:  A Selim Yavuz; Peter E Lipsky; Sule Yavuz; Dean D Metcalfe; Cem Akin
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 4.  Systemic mast cell disease. Analysis of 58 cases and literature review.

Authors:  W D Travis; C Y Li; E J Bergstralh; L T Yam; R G Swee
Journal:  Medicine (Baltimore)       Date:  1988-11       Impact factor: 1.889

5.  Molecular characterization of B cell clonal expansions in the liver of chronically hepatitis C virus-infected patients.

Authors:  V Racanelli; D Sansonno; C Piccoli; F P D'Amore; F A Tucci; F Dammacco
Journal:  J Immunol       Date:  2001-07-01       Impact factor: 5.422

6.  Monoclonality in B-lymphoproliferative disorders detected at the DNA level.

Authors:  K J Trainor; M J Brisco; C J Story; A A Morley
Journal:  Blood       Date:  1990-06-01       Impact factor: 22.113

7.  Urticaria pigmentosa and acute lymphoblastic leukemia.

Authors:  J L Fromer; N Jaffe
Journal:  Arch Dermatol       Date:  1973-02

8.  The Kit-activating mutation D816V enhances stem cell factor--dependent chemotaxis.

Authors:  M L Taylor; J Dastych; D Sehgal; M Sundstrom; G Nilsson; C Akin; R G Mage; D D Metcalfe
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

9.  Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia.

Authors:  K Sotlar; T Marafioti; H Griesser; J Theil; C Aepinus; R Jaussi; H Stein; P Valent; H P Horny
Journal:  Mol Pathol       Date:  2000-08

10.  An immunohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional mast cells.

Authors:  Cem Akin; Elaine S Jaffe; Mark Raffeld; Arnold S Kirshenbaum; Trisha Daley; Pierre Noel; Dean D Metcalfe
Journal:  Am J Clin Pathol       Date:  2002-08       Impact factor: 2.493

View more
  8 in total

1.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.

Authors:  Thomas Kristensen; Hanne Vestergaard; Michael Boe Møller
Journal:  J Mol Diagn       Date:  2011-03       Impact factor: 5.568

2.  Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.

Authors:  Maria Jara-Acevedo; Cristina Teodosio; Laura Sanchez-Muñoz; Ivan Álvarez-Twose; Andrea Mayado; Carolina Caldas; Almudena Matito; José M Morgado; Javier I Muñoz-González; Luis Escribano; Andrés C Garcia-Montero; Alberto Orfao
Journal:  Mod Pathol       Date:  2015-06-12       Impact factor: 7.842

3.  An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).

Authors:  H-P Horny; K Sotlar; F Stellmacher; P Valent; J Grabbe
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

Review 4.  Ancillary techniques in bone marrow pathology: molecular diagnostics on bone marrow trephine biopsies.

Authors:  Falko Fend; Oliver Bock; Markus Kremer; Katja Specht; Leticia Quintanilla-Martinez
Journal:  Virchows Arch       Date:  2005-10-18       Impact factor: 4.064

Review 5.  Comprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.

Authors:  Oscar González-López; Javier I Muñoz-González; Alberto Orfao; Iván Álvarez-Twose; Andrés C García-Montero
Journal:  Cancers (Basel)       Date:  2022-05-18       Impact factor: 6.575

Review 6.  Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.

Authors:  B M Jensen; C Akin; A M Gilfillan
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

Review 7.  Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?

Authors:  Katja Woidacki; Ana Claudia Zenclussen; Frank Siebenhaar
Journal:  Front Immunol       Date:  2014-05-19       Impact factor: 7.561

Review 8.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.